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Macula densa nitric oxide synthase: Expression, regulation, and
function. The type 1 brain nitric oxide synthase (bNOS) isoform
occurs in macula densa (MD) cells where it functions to vasodilate
the afferent arteriole and blunt expression of tubuloglomerular
feedback (TGF). Dietary salt restriction enhances bNOS expres-
sion, yet microperfusion studies with NOS inhibitors imply that it
is functionally inactive. We thus assessed the hypothesis that
reduced L-arginine (L-Arg) availability during low salt (LS) intake
limits MD NO generation. Maximal TGF responses were re-
corded during Henle’s loop perfusion with artificial tubular fluid
(ATF). Microperfusion of L-Arg into the MD of LS, but not
normal or high-salt (HS) rats blunted maximal TGF responses
(8.0 6 0.4 to 6.0 6 0.5 mm Hg; N 5 23; P , 0.01). Response to
L-Arg was stereospecific, inhibited by coperfusion with mono-
methyL-L-arginine (L-NMA), and dependent on system y1 trans-
port, because it was blocked by coperfusion with the competitors
L-lysine or L-homoarginine. Absorption of [3H]-L-Arg from the
perfused loop, via an L-Arg— or L-homoarginine—inhibitable
process, was enhanced during HS. Salt restriction thus diminishes
TGF attenuation by NO in the MD despite enhanced bNOS
expression because of limited delivery and/or uptake of L-Arg via
system y1. This defines a novel mechanism of renal microcircu-
latory adaptation to salt restriction via L-Arg—dependent
changes in TGF.
In pioneering experiments, Thurau and Schnermann
showed that increasing Na reabsorption at the macula
densa (MD) led to a fall in single-nephron glomerular
filtration rate (SNGFR) [1] that they termed tubuloglo-
merular feedback (TGF). This response entails vasocon-
striction of the afferent arteriole, but the constrictor medi-
ators remain to be defined precisely [2]. Wilcox et al have
proposed recently that nitric oxide (NO) generated in the
MD by L-arginine (L-Arg) metabolism via NO synthase
(NOS) is a negative mediator blunting expression of TGF
responses [3]. Three or more NOS isoforms are expressed
in the normal rat kidney [4]. Brain-type NOS (bNOS) is
expressed densely in MD cells [3, 5, 6]. bNOS is expressed
additionally in some adjacent thick ascending limb (TAL)
cells, cells of Bowman’s capsule, some intrarenal nerves,
and tubular structures [5, 6]. Both bNOS mRNA [4, 6–9]
and nicotinamide adenine dinucleotide phosphate diapho-
rase [3] are also expressed in the MD.
MD solute absorption appears to activate NOS and
generate NO that blunts the expression of TGF-induced
reductions in glomerular capillary hydraulic pressure
(PGC). Thus, microperfusion of N
G-methyl-L-Arg (L-
NMA) into the lumen of the MD or adjacent interstitium
via the peritubular capillaries enhances the TGF response
in normal rats [3]. This effect of L-NMA is stereospecific
and is prevented by coperfusion with excess L-Arg (dem-
onstrating dependency on NOS) and by microperfusion of
furosemide and thus depends on MD solute reabsorption.
Studies with L-NMA or the relatively bNOS-specific inhib-
itor 7-nitroindazole have confirmed that blockade of MD
NOS enhances rat TGF responses [10]. In a perfused rat
juxtaglomerular apparatus (JGA) preparation, microperfu-
sion of the MD by nitro-L-Arg methyl ester (L-NAME)
leads to graded constriction of the adjacent afferent arte-
riole [11]. This response is dependent on MD solute
absorption, as it is prevented by MD perfusion with a low
NaCl solution. These studies directly implicate MD NOS in
this response because during MD microperfusion of L-
NAME, the vasodilator response to intraarterial infusion of
acetylcholine, which activates endothelial NO generation,
is preserved. MD microperfusion with L-Arg in normal rats
blunts TGF [12]. Collectively, these studies demonstrate a
powerful MD-afferent arteriolar signaling pathway depen-
dent on NO, which vasodilates the afferent arteriole and
blunts the expression of TGF. MD-derived NO might also
blunt the generation of the signal initiating TGF, as NO, or
its second messenger cGMP, can inhibit TAL solute reab-
sorption [13].
TGF responses are enhanced by dietary salt restriction or
activation of the renin-angiotensin system (RAS) [2, 14].
The immunocytochemical expression of bNOS in the MD is
enhanced by dietary salt restriction [15]. This effect is
dependent partly on enhanced RAS activity, because it
could be blunted by the angiotensin II type 1 (AT1)
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receptor antagonist, losartan, in low-salt rats [15]. Studies
of microdissected vascular poles containing intact MD
segments have shown enhanced mRNA expression for
bNOS in rats adapted to low salt intake that parallels
increases in afferent arteriolar renin gene expression [7, 8].
Despite this clear evidence for enhanced expression of
bNOS mRNA and protein in the MD during salt restric-
tion, results from functional studies suggest that the MD-
afferent arteriolar NO signaling pathway is inactive in
salt-restricted rats. Thus, microperfusion of L-NMA into
the MD of salt-restricted rats fails to modify TGF, whereas
similar microperfusions in rats adapted to normal or high
salt intake regularly enhance the response [10, 16]. These
studies were designed to examine the hypothesis that
delivery and/or uptake of L-Arg at the MD limits the
blunting of TGF by NO generation during salt restriction.
L-Arg is transported across cell membranes by Na-
dependent and -independent pathways, the latter including
system y1, for which L-Arg competes with L-ornithine,
L-lysine, and L-homoarginine [17–19]. L-Arg is transported
both into and out of the TAL by a saturable, carrier-
mediated process [20, 21].
METHODS
Male Sprague-Dawley rats (220 to 300 g) were fed
identical diets (Teklad, Madison, WI, USA) with a low salt
(LS; Na content 0.03 g/100 g) or high salt (HS; Na content
2.3 g/100 g) content for 8 to 12 days prior to testing. The LS
diet is sufficient for normal growth over this period. Rats
were prepared for micropuncture, microperfusion, and
TGF studies, as described in detail previously [22]. In brief,
the TGF response was assessed from changes in proximal
stop-flow pressure (PSF) recorded via an ultramicropipette
inserted in a proximal tubule upstream from a wax block
and connected to a servo-null micropressure recorder (IPS,
La Jolla, CA, USA). TGF was activated maximally by
microperfusion of artificial tubular fluid (ATF) containing
vehicle or drugs from the end proximal tubule into the loop
segment at 40 nl/min. Responses of HS and LS rats were
compared in the following protocols:
Series 1. TGF responses to microperfusion of L-Arg:
Effects of salt intake and system y1 transport
TGF responses were contrasted in nephrons of LS rats
(N 5 23) or HS rats (N 5 19) during microperfusion of
ATF plus vehicle or ATF plus L-Arg (1023 M) perfused
alone. Additional studies were undertaken in nephrons
perfused with L-lysine (2 3 1023 M) or L-homoarginine (2 3
1023 M) perfused alone or with L-Arg as competitive
inhibitors of system y1 transport.
Series 2. Absorption of [3H]-L-Arg from perfused loop of
Henle (LH): Effects of salt intake and system y1
transport
ATF containing [3H]-L-Arg (15 cpm/nl; Amersham, Ar-
lington Heights, IL, USA) and [14C]-inulin (15 cpm/nl;
ICN, Costa Mesa, CA, USA) as a recollection marker was
microperfused from a precisely calibrated microperfusion
pump into the late proximal tubule and collected upstream
from an oil block at the early distal tubule. Perfusions were
delivered at 20 nl/min, and collections were made over
2-minute periods. To the perfusates were added vehicle,
L-Arg (1 mM), or L-homoarginine (1 mM). Aliquots of the
perfusate and the collectate were counted in scintillation
vials.
Data were analyzed by analysis of variance, and results
were considered statistically significant at P , 0.05. Data
are presented as mean 6 SEM.
Fig. 1. Percentage changes in maximal tubuloglomerular feedback
(TGF) responses of nephrons from rats adapted to low (A) or high (B) salt
intakes during orthograde perfusion of the loop of Henle at 40 nl/min with
artificial tubular fluid (ATF) containing L-arginine (1023 M), L-lysine
(2 3 1023 M), or L-homoarginine (2 3 1023 M), singly or together.
Means 6 SEM. ** P , 0.01 versus ATF 1 vehicle.
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RESULTS
There were no significant differences in body wt, kidney
weight, or blood pressure in HS and LS rats. Moreover,
PSF during zero loop perfusion was similar (LS, 36.1 6 0.6
vs. HS, 37.2 6 0.8 mm Hg; N 5 24; NS). Therefore, TGF
responses are presented as changes in PSF during LH
perfusion at 40 nl/min compared with zero perfusions.
During LH perfusion with ATF 1 vehicle, maximal TGF
responses, assessed from changes in PSF, were enhanced in
nephrons of salt-restricted rats (LS, 8.1 6 0.4 vs. HS, 6.6 6
0.4 mm Hg; P , 0.01).
For series 1, the addition of L-Arg to ATF perfusates
blunted the maximal TGF responses in nephrons of LS rats
(Fig. 1A). Microperfusion of L-lysine or L-homoarginine did
not alter TGF responses when given alone but, when
coperfused with L-Arg, blocked the effects of L-Arg in
blunting TGF responses. In contrast, L-Arg did not signif-
icantly change TGF responses in nephrons of HS rats (Fig.
1B). L-Lysine or L-homoarginine had no effects whether
microperfused alone or with L-Arg. We conclude that L-Arg
delivery and uptake from the tubular lumen via system y1
blunts TGF specifically in nephrons of salt-restricted rats.
For series 2, 90% to 110% of the [14C]-inulin microper-
fused from the late proximal tubule was collected at the
early distal tubule in each nephron. Absorption of [3H]-L-
Arg from the perfused LH averaged 92% 6 3% and did not
differ between LS and HS rats. However, the mechanism of
absorption was strongly salt dependent. Addition of excess
L-Arg significantly (P , 0.01) blunted [3H]-L-Arg absorp-
tion, but this effect was significantly (P , 0.01) greater in
HS than in LS rats. Likewise, addition of L-homoarginine
significantly (P , 0.01) blunted [3H]-L-Arg absorption.
This effect also was significantly (P , 0.05) greater in HS
than in LS rats. We conclude that dietary salt restriction
diminishes the saturable y1 system reabsorptive flux of
L-Arg from the perfused LH.
Fig. 2. Cell diagram showing hypotheses for regulation of macula densa cell brain nitric oxide synthase (bNOS). Solute absorption via an Na1/K1/2Cl,
furosemide-inhibitable luminal cotransporter activates bNOS, perhaps via increases in intracellular calcium concentration. L-Arginine uptake into the
cell via system y1 is inhibited by L-ornithine, L-lysine, and L-homoarginine and by symmetric and asymmetric dimethylarginine (SDMA and ADMA)
and monomethyl L-arginine (L-NMA). ADMA and L-NMA also inhibit bNOS activity. NO generated in the macula densa cell is degraded by interaction
with oxygen radicals (O2
2) to peroxynitrite (ONOO2).
Wilcox and Welch: Macula densa NOS S-55
DISCUSSION
The finding that bNOS is heavily expressed in the MD
during dietary salt restriction [15], but apparently does not
function to produce NO, because TGF is unaltered during
NOS blockade [10, 16] implies that the NOS expressed
might not be functional. However, these studies demon-
strate a robust blunting of TGF by microperfusion of L-Arg
into the MD of LS rats. This response to MD perfusion
with L-Arg apparently entails NO generation, as it is
stereospecific and blocked by coperfusion of L-NMA [23].
Therefore, the NOS expressed during salt restriction is
functional but apparently is limited by L-Arg availability.
These single-nephron studies have parallels with whole-
kidney results in which dietary salt restriction reduces
plasma levels and rates of excretion of the NO metabolites,
NO2 1 NO3 and cGMP, enhances the renal vasoconstrictor
response to NOS blockade with L-NAME [24], and in-
creases the NOS-dependent renal vasodilator response to
L-Arg [25]. These whole-kidney data complement the more
specific single-nephron studies and indicate that dietary salt
restriction diminishes NO generation via an L-Arg—de-
pendent mechanism. Rat plasma [L-Arg] averages 80 mM
during salt restriction but increases significantly to 160 mM
during salt loading [26], demonstrating a systemic effect of
salt intake on arginine metabolism. However, the contrast
between this evidence of L-Arg—stimulated NO genera-
tion and the extracellular concentrations that are one or
two orders of magnitude above the Km for NOS measured
in purified systems has been considered paradoxical [27].
Nevertheless, the kidney generates methylarginine deriva-
tives that both inhibit arginine uptake from the LH via
system y1 and inhibit NOS activity in the MD [28].
Immunocytochemical studies have located the MD as a site
of expression of the enzyme NG-NG-dimethylarginine dim-
ethylaminohydrolase that recycles dimethylarginines to cit-
rulline [28]. Therefore, cellular levels of L-Arg in the MD
may be limited because of competition with dimethylargi-
nine for uptake, and the intracellular NOS activity in vivo
may be inhibited by the presence of these methylarginines.
This could account for a higher apparent Km for L-Arg in
vivo.
This finding of a saturable, carrier-mediated L-Arg re-
absorptive pathway in the LH, for which L-homoarginine
competes, confirms previous studies [21]. Our data are
consistent with system y1 transport, in which L-Arg com-
petes with other cationic amino acids [17–19]. Tracer
quantities of L-Arg were almost completely absorbed from
the LH, regardless of salt intake. However, the pathways of
absorption differed significantly. During dietary salt load-
ing, absorption through the system y1 transport pathway
was increased substantially. Because luminal L-Arg uptake
into MD cells for NO generation also depends on system y1
transport, the results suggest that, during HS, the robust
L-Arg uptake into the MD via system y1 accounts for the
lack of response to provision of further L-Arg via the
tubular lumen. In contrast, during salt restriction, system
y1 uptake of L-Arg is greatly diminished. This is com-
pounded by reduced plasma L-Arg concentration [26] and,
probably, enhanced reabsorption of L-Arg proximally via
Na1-linked absorption [29], which would limit arginine
delivery to the MD segment and uptake into cells. This
could account for the requirement of extra L-Arg during LS
to generate NO via MD bNOS.
In conclusion, these studies demonstrate that MD NO
generation is limited during salt restriction. This is impor-
tant physiologically because a limited NO generation could
contribute to TGF enhancement and thereby to renal
vasoconstriction. The failure of NO generation cannot be
ascribed to decreased NOS expression but rather to de-
creased L-Arg availability. Reduced availability can be
ascribed to a reduced plasma level, enhanced proximal
reabsorption, and diminished uptake in the LH and MD
cells via sodium-independent system y1. These findings
that L-Arg levels and transport are regulated and that
arginine can act systemically and within the kidney to
determine NOS activity, elevate it to a level of a hormone
involved in body fluid volume homeostasis. These hypoth-
eses are summarized in Figure 2.
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APPENDIX
Abbreviations used in this article are: ATF, artificial tubular fluid;
bNOS, brain nitric oxide synthase; HS, high salt; JGA, juxtaglomerular
apparatus; LH, loop of Henle; L-Arg, L-arginine; L-NMA, monomethyL-
L-arginine; L-NAME, nitro-L-Arg methyl ester; LS, low salt; MD, macula
densa; NO, nitric oxide; NOS, nitric oxide synthase; PGC, glomerular
capillary hydraulic pressure; PSF, proximal stop-flow pressure; RAS,
renin-angiotensin system; SNGFR, single-nephron glomerular filtration
rate; TAL, thick ascending limb; TGF, tubuloglomerular feedback.
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